EGFR and non-small cell lung adenocarcinoma: For example, in non-small cell lung adenocarcinoma, the efficacy of tyrosine kinase inhibitors, including gefitinib and erlotinib, is linked to epidermal growth factor receptor (EGFR) mutations, which are much more prevalent among Asian patients than EAs (30% vs. 7%) [15–17].